| 17.08 -3.02 (-15.02%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.63 |
1-year : | 40.65 |
| Resists | First : | 27.93 |
Second : | 34.81 |
| Pivot price | 22.17 |
|||
| Supports | First : | 16.81 |
Second : | 13.99 |
| MAs | MA(5) : | 19.59 |
MA(20) : | 23.74 |
| MA(100) : | 27.2  |
MA(250) : | 21.79 |
|
| MACD | MACD : | -3.4 |
Signal : | -3.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 15 |
| RSI | RSI(14): 26.5 |
|||
| 52-week | High : | 42.14 | Low : | 7.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FTH ] has closed above bottom band by 8.7%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.19 - 20.31 | 20.31 - 20.4 |
| Low: | 16.57 - 16.71 | 16.71 - 16.81 |
| Close: | 16.9 - 17.1 | 17.1 - 17.25 |
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway.
Fri, 23 Oct 2026
Faeth Therapeutics (FTH) Reports Promising Preclinical Data on P - GuruFocus
Fri, 23 Oct 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 22, 2026 - BioSpace
Mon, 19 Oct 2026
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026 - BioSpace
Sun, 20 Sep 2026
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to S&P Global BMI Index - www.marketscreener.com
Fri, 18 Sep 2026
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 80.9 (%) |
| Shares Short | 2,070 (K) |
| Shares Short P.Month | 1,100 (K) |
| EPS | -60.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.8 % |
| Return on Equity (ttm) | -195.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 2.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|